Chemists and other professionals from drug companies and academics in various specialties of medicine evaluate the current status in the race between drug designers and viral evolution. Among their perspectives are inhibiting HIV entry, helicase-primase inhibitors as a new approach to combating herpes simplex virus and varicella zoster virus, alkoxyalkyl ester pro-drugs of antiviral nucleoside phosphate and phosphonates, maribavir as a novel benzimidazole ribonucleoside for preventing and treating cytomegalovirus diseases, lethal mutagenesis as an unconventional approach to combating HIV, silencing viruses with antiviral RNAi, and neuraminidase inhibitors as anti-influenza agents. Annotation ©2012 Book News, Inc., Portland, OR (booknews.com)